Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients

Table 1

Clinical characteristics of DLBCL patients ().

Characteristics	Liver dysfunction group, n (%)	Normal liver function group, n (%)	value
Average age (years)	56.7	55.8	0.760
Age (years) > 60	35 (40%)	140 (51%)	0.088
Sex (male)	56 (64%)	156 (57%)	0.195
IPI score			<0.001
Low	26 (30%)	147 (53%)
Low-intermediate	17 (20%)	54 (19%)
High-intermediate	20 (23%)	43 (16%)
High	24 (27%)	32 (12%)
Ann Arbor stages III-IV	57 (66%)	104 (38%)	<0.001
Number of extranodal sites ≥ 2	35 (40%)	90 (33%)	0.192
Lymphomatous hepatic infiltration	7 (8%)	9 (3%)	0.058
LDH > normal	60 (69%)	94 (34%)	<0.001
Performance status (ECOG) ≥ 2	25 (29%)	27 (10%)	<0.001
Presence of B symptoms	33 (38%)	59 (21%)	0.002
HBV-DNA positive	5 (6%)	8 (3%)	0.213
Hepatitis C virus	1 (1%)	4 (1%)	0.655
Liver enzyme (median values [range], IU/L)
ALT	41.0 (10.0–577.0)	16.5 (1.0–59.0)	<0.001
AST	45.0 (7.0–678.0)	19.0 (9.0–39.0)	<0.001
γ-GT	65.5 (1.0–707.0)	18.0 (1.0–64.0)	<0.001
ALP	89.0 (21.0–1013.0)	69.0 (39.0–122.0)	<0.001
Serum cytokines (median values [range])
IL-2R (U/mL)	1894.5 (232.0–7500.0)	615.5 (52.1–7500.0)	<0.001
IL-6 (pg/mL)	8.9 (2.0–194.0)	3.6 (2.0–69.1)	<0.001
IL-8 (pg/mL)	43.7 (6.6–3533.0)	54.0 (5.0–2849.0)	0.207
IL-10 (pg/mL)	7.1 (5.0–1000.0)	5.0 (4.0–1000.0)	<0.001
TNF-α (pg/mL)	19.2 (4.0–275.0)	9.5 (4.0–151.0)	<0.001
Treatment			<0.001
R-CHOP	75 (86%)	265 (96%)
CHOP	4 (5%)	11 (4%)
Supportive care	8 (9%)	0 (0%)
CR (%)	70.0	85.8	0.004